BLISS GVS PHARMA LTD.

November 24, 2026

To The Manager, Listing Department **National Stock Exchange of India Ltd.** Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: **BLISSGVS**	To General Manager, Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: **506197**

Subject: Intimation regarding certificate of Eudra Good Manufacturing Practice (EU GMP) compliance for Company's Manufacturing Facility at Palghar, Maharashtra, India

Ref.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company's manufacturing facility situated at Survey No. 43-44, Vevoor Village, Palghar – 401404, Maharashtra, India, has received certificate of Eudra Good Manufacturing Practice (EU GMP) Compliance from the National Authority of Medicines and Health Products, Portugal, being the Regulatory Authority of Portugal, for tablet and semi-solid dosage forms.

This achievement reaffirms the Company's commitment to maintaining the highest standards of quality, safety and regulatory compliance across its operations. It reflects the Company's continued focus on operational excellence and adherence to the stringent requirements and standards prescribed by global regulatory authorities.

This intimation is made for your information and record.

Thanking you,
For **Bliss GVS Pharma Limited**

ADITI HIMANSHU BHATT
Digitally signed by ADITI HIMANSHU BHATT
Date: 2026.11.24 19:48:43 +05'30'

Aditi H. Bhatt
Company Secretary & Compliance Officer